

# Alessandra Fanciulli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3762227/publications.pdf>

Version: 2024-02-01

64  
papers

3,658  
citations

304368

22  
h-index

138251

58  
g-index

68  
all docs

68  
docs citations

68  
times ranked

3540  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of cardiovascular autonomic failure in the differential diagnosis of $\alpha$ -synucleinopathies. <i>Neurological Sciences</i> , 2022, 43, 187-198.	0.9	5
2	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy. <i>Clinical Autonomic Research</i> , 2022, 32, 103-114.	1.4	7
3	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	2.2	222
4	European Academy of Neurology guidance for developing and reporting clinical practice guidelines on rare neurological diseases. <i>European Journal of Neurology</i> , 2022, 29, 1571-1586.	1.7	5
5	Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders. <i>European Journal of Neurology</i> , 2022, 29, 2772-2780.	1.7	3
6	Bedside Assessment of Autonomic Dysfunction in Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2277-2281.	1.5	3
7	A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson's disease with dementia. <i>Brain Communications</i> , 2022, 4, .	1.5	3
8	Women in clinical autonomic research and the autonomic societies: how far have we come in thirty years?. <i>Clinical Autonomic Research</i> , 2021, 31, 23-26.	1.4	1
9	Cardiovascular autonomic failure in Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021, 1, 119-146.	0.1	0
10	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clinical Autonomic Research</i> , 2021, 31, 157-164.	1.4	22
11	Insular damage causing transient baroreflex dysfunction in a teenager with Allgrove syndrome. <i>Clinical Autonomic Research</i> , 2021, 31, 581-584.	1.4	1
12	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness. <i>Clinical Autonomic Research</i> , 2021, 31, 369-384.	1.4	48
13	Laboratory-supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 322-340.	0.8	7
14	Neuropathology of multiple system atrophy: Kurt Jellinger's legacy. <i>Journal of Neural Transmission</i> , 2021, 128, 1481-1494.	1.4	6
15	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1052-1060.	0.8	6
16	Rethinking neurological attitudes towards vasovagal syncope: The European Federation of Autonomic Societies (EFAS) recommendations regarding tilt table testing. <i>European Journal of Neurology</i> , 2021, 28, e69-e70.	1.7	1
17	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness : Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). <i>Autonomic Neuroscience: Basic and Clinical</i> . 2021. 233. 102792.	1.4	22
18	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. <i>Movement Disorders</i> , 2021, 36, 2703-2705.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Female sexual dysfunction in multiple system atrophy: a prospective cohort study. <i>Clinical Autonomic Research</i> , 2021, 31, 713-717.	1.4	10
20	Autonomic failure: a neglected presentation of Parkinson's disease. <i>Lancet Neurology</i> , The, 2021, 20, 781-782.	4.9	6
21	Characterization of gait variability in multiple system atrophy and Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 1770-1779.	1.8	18
22	Cardiovascular autonomic testing in the work-up of cerebellar ataxia: insight from an observational single center study. <i>Journal of Neurology</i> , 2020, 267, 1097-1102.	1.8	5
23	Management of Orthostatic Hypotension in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, S57-S64.	1.5	34
24	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020, 95, e2854-e2865.	1.5	25
25	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
26	Cardiovascular autonomic function testing in multiple system atrophy and Parkinson's disease: an expert-based blinded evaluation. <i>Clinical Autonomic Research</i> , 2020, 30, 255-263.	1.4	10
27	Which Autonomic Features Distinguish Multiple System Atrophy and When. <i>Movement Disorders</i> , 2020, 35, 902-903.	2.2	0
28	Anticoagulation therapy in older patients at risk for syncopal and not-syncopal fall and/or frailty. An AcEMC-GIMSI multidisciplinary consensus document. <i>Emergency Care Journal</i> , 2020, 16, .	0.2	0
29	Effects of self-administered cannabidiol in a patient with multiple system atrophy. <i>Clinical Autonomic Research</i> , 2020, 30, 355-356.	1.4	6
30	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. <i>Annals of Neurology</i> , 2020, 88, 643-645.	2.8	27
31	The footprint of orthostatic hypotension in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 107-109.	1.1	3
32	Cognition in multiple system atrophy: a single-center cohort study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 219-228.	1.7	31
33	The Schellong test: detecting orthostatic blood pressure and heart rate changes in German-speaking countries. <i>Clinical Autonomic Research</i> , 2019, 29, 363-366.	1.4	24
34	Urinary retention discriminates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1926-1928.	2.2	19
35	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 60-65.	1.1	23
36	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	2.2	73

#	ARTICLE	IF	CITATIONS
37	Early distinction of Parkinsonian variant multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 440-441.	2.2	21
38	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019, 149, 137-192.	0.9	74
39	Management of supine hypertension in patients with neurogenic orthostatic hypotension. <i>Journal of Hypertension</i> , 2019, 37, 1541-1546.	0.3	60
40	SYNE1-ataxia: Novel genotypic and phenotypic findings. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 210-214.	1.1	11
41	Reply to the letter of Satish R. Rayet al. of 28 August 2018. <i>European Heart Journal</i> , 2019, 40, 71-71.	1.0	1
42	2018 ESC Guidelines for the diagnosis and management of syncope. <i>Russian Journal of Cardiology</i> , 2019, , 130-194.	0.4	6
43	Autonomic function testing in spinocerebellar ataxia type 2. <i>Clinical Autonomic Research</i> , 2018, 28, 341-346.	1.4	13
44	Practical Instructions for the 2018 ESC Guidelines for the diagnosis and management of syncope. <i>European Heart Journal</i> , 2018, 39, e43-e80.	1.0	149
45	2018 ESC Guidelines for the diagnosis and management of syncope. <i>European Heart Journal</i> , 2018, 39, 1883-1948.	1.0	1,200
46	Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS). <i>Clinical Autonomic Research</i> , 2018, 28, 355-362.	1.4	176
47	Autonomic function testing in Friedreich's ataxia. <i>Journal of Neurology</i> , 2018, 265, 2015-2022.	1.8	14
48	Cerebral Vasoreactivity in Parkinson's Disease: A Pilot Study. <i>International Journal of Clinical Research &amp; Trials</i> , 2018, 3, .	1.6	1
49	Very late-onset pure autonomic failure. <i>Movement Disorders</i> , 2017, 32, 1106-1108.	2.2	4
50	Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. <i>Journal of Neural Transmission</i> , 2017, 124, 1567-1605.	1.4	74
51	Autonomic History Taking and Key Symptoms: Where Is the Autonomic Disease?. , 2017, , 15-36.		1
52	Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 156-160.	0.8	35
53	Cardiovascular dysfunction in untreated Parkinson's disease: A multi-modality assessment. <i>Journal of the Neurological Sciences</i> , 2016, 370, 251-255.	0.3	43
54	Supine hypertension in Parkinson's disease and multiple system atrophy. <i>Clinical Autonomic Research</i> , 2016, 26, 97-105.	1.4	87

#	ARTICLE	IF	CITATIONS
55	Multiple-System Atrophy. <i>New England Journal of Medicine</i> , 2015, 372, 1374-1376.	13.9	53
56	Multiple-System Atrophy. <i>New England Journal of Medicine</i> , 2015, 372, 249-263.	13.9	600
57	Sex and age effects on cardiovascular autonomic function in healthy adults. <i>Clinical Autonomic Research</i> , 2015, 25, 317-326.	1.4	24
58	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1393-1397.	1.1	33
59	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. <i>Journal of Neurology</i> , 2014, 261, 1291-1299.	1.8	47
60	The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study. <i>European Journal of Medical Research</i> , 2013, 18, 60.	0.9	12
61	Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 601-603.	1.4	9
62	Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease. <i>Pharmacological Reports</i> , 2011, 63, 1056-1060.	1.5	4
63	The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders. <i>Current Neuropharmacology</i> , 2011, 9, 278-288.	1.4	76
64	Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 355-357.	2.2	10